Topical Tacrolimus in Ocular Disease: A Narrative Review of Mechanism of Action and Therapeutic Applications

PURPOSE: Immune-mediated inflammatory disorders of the ocular surface and anterior segment frequently require sustained immunosuppression, yet prolonged topical corticosteroid use carries the risk of glaucoma, cataract, and infection. Tacrolimus, a macrolide calcineurin inhibitor, has emerged as a steroid-sparing alternative for T-cell-mediated ocular disease. This review summarizes the mechanism of action, ocular pharmacology, clinical applications, and safety profile of topical tacrolimus. METHODS: Narrative synthesis of the peer-reviewed literature. RESULTS: Tacrolimus binds the immunophilin FK506-binding protein 12; the resulting complex inhibits the phosphatase calcineurin, preventing dephosphorylation and nuclear translocation of the nuclear factor of activated T-cells (NFAT) and thereby suppressing transcription of interleukin-2 and a broad program of pro-inflammatory cytokines. The downstream result is reduced activation across the Th1, Th2, and Th17 lineages, diminished T-follicular helper and B-cell responses, stabilization of mast cells and eosinophils, and anti-angiogenic effects. Compounded topical formulations (typically 0.01%-0.1%) penetrate the cornea and reach therapeutic aqueous concentrations. Topical tacrolimus has shown efficacy in vernal and atopic keratoconjunctivitis, anterior uveitis, scleritis, ocular graft-versus-host disease, cicatrizing conjunctivitis, Thygeson superficial punctate keratitis, autoimmune polyglandular syndrome-1-associated keratitis, and corneal graft rejection. CONCLUSIONS: Topical tacrolimus is an effective steroid-sparing immunomodulator for a broad spectrum of T-cell-mediated ocular disease, with a favorable safety profile notable for the absence of steroid-related rises in intraocular pressure or cataractogenesis. Standardized formulations and prospective comparative trials remain priorities.